Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-11-21
2006-11-21
Kam, Chin-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C435S069700, C435S325000, C435S320100, C530S350000, C514S002600, C514S012200, C536S023700
Reexamination Certificate
active
07138127
ABSTRACT:
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
REFERENCES:
patent: 4189426 (1980-02-01), Li
patent: 4481139 (1984-11-01), Folkers et al.
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4719231 (1988-01-01), Umezawa et al.
patent: 5410019 (1995-04-01), Coy et al.
patent: 5714468 (1998-02-01), Binder
patent: 5744131 (1998-04-01), Edwards et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5846216 (1998-12-01), Gonzales et al.
patent: 5861284 (1999-01-01), Nishimura et al.
patent: 5891842 (1999-04-01), Kream
patent: 5965406 (1999-10-01), Murphy
patent: 5989545 (1999-11-01), Foster et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: WO95/32738 (1995-12-01), None
patent: 9633273 (1996-10-01), None
patent: 98/01754 (1998-01-01), None
patent: 9807864 (1998-02-01), None
patent: 9917806 (1999-04-01), None
Ueda, “In Vivo Molecular Signal Transduction . . . ” Jpn J Pharmacol. vol. 79, 1999, pp. 263-268, only abstract.
Nichols et al, “Transmission of Chronic Nociception . . . ” Science, vol. 286, Nov. 1999, pp. 1558-1561.
Lopes & Couture, “Localization of Bradykinin-Like . . . ” Neuroscience, vol. 78, 1997, pp. 481-497, only abstract.
Vigna et al, “Characterization of Antibodies . . . ” J Nerosci, vol. 14, 1994, pp. 834-845, only abstract.
Principles of Neural Science Third Edition, Edited by Kandel et al., one page.
Babenko etal, “Experimental Human Muscle Pain . . . ” Pain, vol. 82, 1999, pp. 1-8.
Garrison & Rall, “Autacoids; Drug Therapy of Inflammation”.
Henry, “Substance P and Inflammatory . . . ” Disease Therapy, 1993.
Tsuda et al “In Vivo Pathway . . . ” Br J Pharmacol, vol. 127, 1999, pp. 449-456.
Welch et al, “Sensitivity of Emryonic Rat . . . ” Toxicon, vol. 38, 2000, pp. 245-258.
Mathias et al, “Topical Casaicin for Chronic Neck Pain..” Abstract,American Journal of Physical Medicine &Rehabilitation,vol. 74, 1995,pp. 39-44.
Furst, “Transmitters Involved in Antinociception in the Spinal Cord” Abstract, Brain Research Bulletin, vol. 48, 1999, pp. 129-141.
Poulain et al, Inhibition of Transmitter Release bybotulinumNeurotoxin A Eur.J.Biochem, vol. 185, 1989, pp. 197-203.
van Hagen et al, “Neuropeptides and their Receptors” Ann Med, vol. 31 Suppl2, pp. 15-22.
XP-000869767, Intracellular Messengers Contributing to Persistent Nociception and Hyperalgesia Induced by L-Glutamate and Substance P in the Rat Formalin Pain Model, Terence J. Coderre, and Kiran Yashpal, European Journal of Neuroscience, vol. 6, pp. 1328-1334, 1994.
XP-002091075, Histochemical Localization of Galactose-Containing Glycoconjugates in Sensory Neurons and Their Processes in the Central and Peripheral Nervous System of the Rat, Wolfgang J. Streit, et al., The Journal of Histochemistry and Cytochemistry, vol. 33, No. 10, pp. 1042-1052, 1985.
XP-000857076, Mosaic Structures of Neurotoxins Produced fromClostridium botulinumtypes C and D organisms, Moriishi et al., Biochimica et Biophysica Acta, 1307 (1996) 123-126.
XP001011356, Berge, O-G et al., “Selective Neurotoxic Lesions of Descending Serotonergic and Noradrenergic Pathways in the Rat”; Journal of Neurochemistry; 44(4):1156-1161 (1985).
XP001012206, Benoliel, R et al., “Actions of intrathecal diptheria toxin-substance P fusion protein on models of persistent pain”; Pain; 79(2-3):243-253 (1999).
XP001011386, Garzon, J et al., “Effect of intrathecal injection of pertusis toxin on substance P norepinephrine and serotonin contents in various neural structures of arthritic rats”; Life Sciences; 47(21):1915-1924 (1990).
Ueda, “In Vivo Molecular Signal Transduction . . . ” Jpn J Pharmacol. vol. 79, 1999, pp. 263-268, only abstract.
Nichols et al, “Transmission of Chronic Nociception . . . ” Science, vol. 286, Nov. 1999, pp. 1558-1561.
Lopes & Couture, “Localization of Bradykinin-Like . . . ” Neuroscience, vol. 78, 1997, pp. 481-497, only abstract.
Vigna et al, “Characterization of Antibodies . . . ” J Nerosci, vol. 14, 1994, pp. 834-845, only abstract.
Principles of Neural Science Third Edition, Edited by Kandel et al, one page (1991).
Babenko etal, “Experimental Human Muscle Pain . . . ” Pain, vol. 82, 1999, pp. 1-8.
Garrison & Rall, “Autacoids; Drug Therapy of Inflammation”.
Henry, “Substance P and Inflammatory . . . ” Disease Therapy, 1993.
Tsuda et al “In Vivo Pathway . . . ” Br J Pharmacol, vol. 127, 1999, pp. 449-456.
Welch et al, “Sensitivity of Emryonic Rat . . . ” Toxicon, vol. 38, 2000, pp. 245-258.
Mathias et al, “Topical Casaicin for Chronic Neck Pain..” Abstract,American Journal of Physical Medicine &Rehabilitation,vol. 74,1995,pp. 39-44.
Furst, “Transmitters Involved in Antinociception in the Spinal Cord” Abstract, Brain Research Bulletin, vol. 48, 1999, pp. 129-141.
Poulain et al, Inhibition of Transmitter Release bybotulinumNeurotoxin A Eur.J.Biochem, vol. 185, 1989, pp. 197-203.
van Hagen et al, “Neuropeptides and Their Receptors” Ann Med, vol. 31 Suppl2, pp. 15-22, (Oct. 1999).
Allergan Inc.
Kam Chin-Min
Stout, Uxa Buyan & Mullins, LLP
LandOfFree
Clostridial toxin derivatives and methods for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clostridial toxin derivatives and methods for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridial toxin derivatives and methods for treating pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668742